ArticleThe journal of nutrition, health & aging2026
Prognostic role of myosteatosis in predicting MACE and mortality after TAVR: insights from CT-based body composition analysis.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the prognostic value of computed tomography (CT)-defined myosteatosis (fat infiltration within muscle tissue) and low muscle mass (loss of muscle mass) for predicting major adverse cardiac events (MACE) and all-cause mortality among patients undergoing transcatheter aortic valve replacement (TAVR).
methodsMyosteatosis was defined as intramuscular adipose tissue (IMAT) exceeding 8.72 cm² in men and 4.58 cm² in women at the 12th thoracic vertebra level, while low muscle mass was defined as the sex-specific first tertile of the paravertebral muscle index (PMI). The primary endpoint was MACE (cardiac death, unstable angina, nonfatal myocardial infarction, nonfatal stroke, heart failure hospitalization), the secondary endpoint was all-cause mortality. We used Cox proportional hazards regression analysis to evaluate the association between body composition and clinical outcomes after TAVR.
resultsA total of 371 patients (198 men and 173 women) were analyzed, 71 patients (19.1%) experienced MACE and 46 patients (12.4%) died. Myosteatosis was associated with higher risks of both MACE (HR: 2.39, 95% CI: 1.13-5.05, P = 0.023) and all-cause mortality (HR: 3.83, 95% CI: 1.54-9.53, P = 0.004). Patients with concomitant myosteatosis and low muscle mass had the worst outcomes, including MACE (HR: 5.06, 95% CI: 2.26-11.32, P < 0.001) and all-cause mortality (HR: 4.70, 95% CI: 1.30-16.95, P = 0.018). Adding myosteatosis to the clinical and low muscle mass model improved prognostic accuracy for both MACE (P = 0.005) and all-cause mortality (P = 0.018).
conclusionCT-derived myosteatosis was associated with adverse outcomes after TAVR and showed modest additional prognostic information beyond low muscle mass and clinical variables. These findings should be externally validated before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.